Roche will have to wait on its big MS drug ap­pli­ca­tion; Pfiz­er ties up with BioIn­vent on new an­ti­bod­ies for can­cer

Roche’s pi­o­neer­ing MS drug Ocre­vus (ocre­lizum­ab) has hit a snag at the FDA. Billed as one of the biggest po­ten­tial block­busters in the pipeline …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.